Showing 8 articles tagged
'Hormone therapy':

Study finds early docetaxel and abiraterone equally effective

8 Sep 2017

Prostate Cancer UK welcomes new data from the STAMPEDE trial that clarifies there is no difference in the benefits offered by both treatments for men newly diagnosed with advanced disease, but now we want the option of earlier abiraterone made available to all men.

New STAMPEDE trial results show earlier abiraterone could improve survival of men with advanced prostate cancer

3 Jun 2017

Announced by researchers at a cancer conference in Chicago, the new findings show earlier and combined use of existing treatments can have a significant impact on advanced disease, but questions remain about its suitability for all men.

What a difference a year in research makes

29 Dec 2016

BLOG: We're only 12 months into our ten-year strategy to tame prostate cancer, but that doesn't mean we haven't already made exciting progress. Our resident expert, Dr Ian Le Guillou, gives us his top ten biggest research breakthroughs (in no particular order) from 2016.

Testosterone 'floods and droughts' treatment shows early promise

1 Dec 2016

A new type of treatment that alternately floods and starves the body of testosterone has shown good early results in men with advanced prostate cancer, according to new findings revealed today.

Behind the Headlines: Does hormone therapy really increase your risk of dementia?

14 Oct 2016

Following reports in the press yesterday of a US study into androgen deprivation therapy – a commonly used treatment for men with prostate cancer in the UK – Prostate Cancer UK's Dr Iain Le Guilliou investigates whether there's any solid proof behind claims it could double the risk of dementia.

New link between testosterone and cancer cell aggression discovered

28 Jul 2016

Prostate Cancer UK and the Movember Foundation reveals new opportunities for diagnosing and treating aggressive prostate cancer

Degarelix approved for men in England whose cancer has spread to the spine

1 Jul 2016

Today’s approval of the hormone therapy, degarelix, by NICE expands on the decision made in 2014 to make it only available to those men who have already developed the symptoms of spinal cord compression. Now, men whose prostate cancer has spread to their spine and who could be at risk of this condition can also access this treatment.

Fighting back against hormone resistance in prostate cancer cells

22 Jan 2014

Prostate Cancer UK scientists show that vitamin D receptor activation can lead to testosterone breaking down in prostate cancer cells.